GRAY
Closed
Graybug Vision Inc
3.23
+0.28 (+9.49%)
Last Update: 23 May 2023 16:30:00
Yesterday: 2.95
Day's Range: 3.09 - 3.46
Send
sign up or login to leave a comment!
When Written:
5
Graybug Vision Inc is a clinical-stage biopharmaceutical company that is focused on developing transformative therapies for the treatment of diseases of the retina and optic nerve. The company was founded in 2011 and is headquartered in Redwood City, California.
Graybug Vision's lead product candidate is GB-102, a novel injectable drug that is being developed for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a leading cause of blindness in people over the age of 65, and GB-102 has the potential to reduce the burden of frequent injections that are required for current treatments.
In addition to GB-102, Graybug Vision is also developing other product candidates for the treatment of retinal diseases, including diabetic macular edema (DME) and primary open-angle glaucoma (POAG).
Graybug Vision has received significant funding from venture capital firms and has also entered into partnerships with pharmaceutical companies for the development of its product candidates. The company is committed to advancing innovative treatments for retinal diseases and improving the lives of patients.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Graybug Vision's lead product candidate is GB-102, a novel injectable drug that is being developed for the treatment of wet age-related macular degeneration (wet AMD). Wet AMD is a leading cause of blindness in people over the age of 65, and GB-102 has the potential to reduce the burden of frequent injections that are required for current treatments.
In addition to GB-102, Graybug Vision is also developing other product candidates for the treatment of retinal diseases, including diabetic macular edema (DME) and primary open-angle glaucoma (POAG).
Graybug Vision has received significant funding from venture capital firms and has also entered into partnerships with pharmaceutical companies for the development of its product candidates. The company is committed to advancing innovative treatments for retinal diseases and improving the lives of patients.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








